CFO
IDYA icon

CVA Family Office’s IDEAYA Biosciences IDYA Stock Holding History

CVA Family Office’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298 Sell
8
-2
-20% -$61 ﹤0.01% 1755
2026
Q1 		$333 Buy
+10
New +$335 ﹤0.01% 1788

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

CVA Family Office's IDYA Position: Q2 2026 in Review

CVA Family Office reduced its IDEAYA Biosciences (IDYA) stake by 20% in Q2 2026, selling an estimated $61 and leaving 8 shares worth $298. The position accounts for ﹤0.01% of the portfolio, ranked #1755.

CVA Family Office first reported a position in IDYA in Q1 2026 and has held it in 2 quarters since. The position peaked at $333 in Q1 2026. 284 funds tracked by Wall St. Rank hold IDYA as of Q2 2026.

  • CVA Family Office held 8 shares of IDEAYA Biosciences worth $298 as of Q2 2026.
  • CVA Family Office sold 2 IDEAYA Biosciences shares in Q2 2026, an estimated $61.
  • IDEAYA Biosciences made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1755 holding.
  • CVA Family Office first reported a position in IDEAYA Biosciences in Q1 2026 and has held it in 2 quarters since.
  • CVA Family Office's IDEAYA Biosciences position peaked at $333 in Q1 2026.
  • 284 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.